Trial Transparency – Time for Pharma to go Above and Beyond?

July 10, 2019

As seen on Open Pharma - Posted July 10, 2019 - Original Article


On 11–12 June 2019, over 60 pharma stakeholders met in Amsterdam at the 8th Annual Publication and Clinical Trial Transparency Conference to discuss the evolving landscape of clinical trial transparency.


Conversations covered the fragmented nature of regulatory requirements in Europe and North America, the need for a more integrated approach to the management of disclosures in registries and publications, and the role of transparency initiatives – that have armed transparency advocates within pharma with the tools to drive disclosure levels that go above and beyond the minimum legal requirements.

Continued on Open Pharma

Previous Article
Preparations for the New EU Portal
Preparations for the New EU Portal

Next Article
As Precision Medicine Grows, So Does the Value of Trial Diversity
As Precision Medicine Grows, So Does the Value of Trial Diversity

Industry experts, including TrialScope CEO Jeff Kozloff, reflect on the recent FDA guidance designed to imp...